Mode
Text Size
Log in / Sign up

Retrospective cohort of 110 children with secondary HLH treated with HLH-94/04 protocolYoung kids with fever and swollen glands need urgent new care plans

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that in-hospital mortality was 13.6% in a retrospective cohort of 110 children with sHLH.

This retrospective analysis examined a cohort of 110 children initially diagnosed with secondary hemophagocytic lymphohistiocytosis (sHLH) at a single hospital. The study aimed to describe the etiological spectrum, treatment approaches, and clinical and laboratory characteristics of this population. The primary exposure was the HLH-94/04 chemotherapy protocol, which was administered to 44.5% of the patients in this cohort.

Clinical and laboratory characteristics were prevalent across the group. Fever was observed in 99.1% of patients, followed by lymphadenopathy in 83.6%, splenomegaly in 77.3%, and hepatomegaly in 66.3%. Infection-associated HLH accounted for 78.2% of cases, with Epstein-Barr virus (EBV) identified as the trigger in 57.3% of instances. Organ involvement included respiratory system issues in over half of the patients and central nervous system involvement in 22.7%. Immunological markers showed decreased NK cell proportion in 75.5% and a reduced CD4+/CD8+ ratio in 59.1%.

Among the 44.5% of patients receiving the HLH-94/04 chemotherapy protocol, 75.5% had EBV infection. The chemotherapy remission rate for this subgroup was 91.9%. However, overall in-hospital mortality remained at 13.6%, with multiple organ dysfunction syndrome (MODS) accounting for 73.3% of fatalities. The median age at diagnosis was 2.67 years, and 52.7% of the cohort was under 3 years old.

Limitations of this study include its retrospective nature and single-center setting, which may affect generalizability. The study did not report specific adverse events or serious adverse events. Consequently, these results describe associations within a specific context rather than establishing universal efficacy or safety profiles for the HLH-94/04 protocol.

Imagine a toddler running a high fever. Their neck feels swollen with lumps, and their belly is hard to the touch. Parents rush to the doctor, hoping for a simple infection. Instead, they face a terrifying storm inside the body.

This is secondary hemophagocytic lymphohistiocytosis, or sHLH. It is a rare but deadly condition where the immune system attacks itself. The body sends out too many immune cells, causing them to eat healthy blood cells and damage vital organs.

Most cases happen in children under three years old. In a recent look at 110 patients, more than half were younger than three. The median age was just two and a half years.

The Virus That Starts the Fire

What triggers this fire? Infection is the main cause. About 78% of the cases were linked to an infection. Epstein-Barr virus, or EBV, was the biggest culprit.

EBV is the virus that causes mononucleosis, or mono. It is very common in children. Yet, in these specific cases, it does not cause a sore throat. Instead, it sets off a chain reaction that the body cannot stop.

Other triggers include rheumatic diseases or cancer. However, the viral trigger is what doctors see most often. Knowing this helps doctors look for the right cause quickly.

Signs You Might Miss

Fever is almost always present. Nearly every child had a high temperature. Swollen glands in the neck were common too. An enlarged spleen was found in most patients.

But there are other clues. The liver often gets involved. Enzymes in the blood show the liver is struggling. Over half the patients had trouble breathing. This means the lungs are part of the storm.

Some children also had trouble with their nervous system. Others developed multiple organ failure. These are the signs that the disease is getting worse fast.

A Factory Gone Haywire

Think of the immune system as a factory. Its job is to make cells that fight germs. In sHLH, the factory goes haywire. It produces too many cells.

These extra cells clog the blood vessels. They eat up red blood cells, platelets, and white blood cells. The body runs out of the parts it needs to function.

It is like a traffic jam on a highway. Cars cannot move. The whole system grinds to a halt. The body becomes weak and sick.

Doctors looked at 110 children treated between 2018 and 2025. They wanted to understand the disease better. They found that standard chemotherapy worked very well for many.

About 45% of patients received a specific chemo protocol. This treatment helped 92% of those patients get better. It stopped the immune storm from raging out of control.

However, the disease is still dangerous. Overall, 13.6% of the children died in the hospital. Most of these deaths happened because organs failed. The liver, lungs, and kidneys stopped working properly.

The Catch With Treatment

But there is a catch. Not everyone responds to the same treatment. The cause of the disease matters. If a virus started it, chemo was very effective.

If a cancer or autoimmune disease caused it, the treatment plan changes. Doctors must find the root cause first. Treating the symptom without fixing the cause often fails.

This means doctors need to look closely at the patient's history. They must check for viruses, cancers, or other diseases. A one-size-fits-all approach does not work here.

What This Means For Families

If your child has a fever and swollen glands, do not wait. These are the classic signs. But look for other clues too.

Check for breathing trouble. Check for an enlarged belly. These signs suggest the storm is spreading. Talk to your doctor about the cause.

Early diagnosis is key. Waiting for the fever to break can be too late. The body changes fast in this condition.

This research helps doctors recognize the disease earlier. It highlights the importance of finding the trigger. Future studies will focus on better ways to stop the storm.

We need more tools to predict who will get sick. We also need to understand why some children survive and others do not.

Research takes time. New treatments are being tested. The goal is to save every child who walks through the door.

This doesn't mean this treatment is available yet.

It is important to remember that this is still a serious illness. Families should talk to their care team. They can explain the risks and the plan.

Understanding the disease helps everyone feel more in control. Knowledge is the best tool we have.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
To describe the etiological spectrum, treatment approaches, clinical and laboratory characteristics in pediatric secondary hemophagocytic lymphohistiocytosis (sHLH) to improve awareness of this severe illness and summarize evolving management strategies. A retrospective analysis was conducted on 110 children initially diagnosed with sHLH at our hospital between January 1, 2018, and June 30, 2025. Among 110 sHLH patients, the median age at diagnosis was 2.67 years (1.17, 5.96), and 52.7% were under 3 years old. Infection-associated HLH accounted for 78.2%, with Epstein-Barr virus (EBV) as the most common trigger (57.3%). The remaining cases were attributed to rheumatic or malignant diseases. The main clinical manifestations included fever (99.1%), lymphadenopathy (83.6%), splenomegaly (77.3%), and hepatomegaly (66.3%). Respiratory system involvement was observed in over half of the patients, while central nervous system involvement (CNSI) and multiple organ dysfunction syndrome (MODS) occurred in 22.7% and 12.8% of cases, respectively. Characteristic laboratory abnormalities were highly prevalent, including pancytopenia (especially thrombocytopenia), hyperferritinemia, hypofibrinogenemia, and elevated soluble interleukin-2 receptor (sCD25). Most patients showed varying degrees of hepatic dysfunction, mainly with elevated enzymes (LDH, AST, ALT, HBDH). Characteristic immunological abnormalities included a decreased NK cell proportion (75.5%) and a reduced CD4+/CD8+ ratio (59.1%). Regarding therapy, 44.5% of patients received the HLH-94/04 chemotherapy protocol, among these, 75.5% had EBV infection, with a chemotherapy remission rate of 91.9%. The overall in-hospital mortality was 13.6%, with MODS accounting for 73.3% of fatalities. Pediatric sHLH is a severe, multisystem inflammatory disorder that predominantly affects infants and young children, with EBV infection as the primary etiological trigger. In addition to the classic HLH-2004 criteria, abnormal liver function indicators, imbalanced lymphocyte subsets and respiratory system involvement were frequent salient features, suggesting their potential utility as auxiliary diagnostic indicators. Furthermore, our findings further emphasize the importance of etiology-based individualized treatment.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.